RSS Feed - Life Sciences - Product Liability - Kaye Scholer LLP
Current Feed: http://www.kayescholer.com/practice/rss.xml?p=life_sciences_product_liability
William Hoffman (05/23/13)
William Hoffman is an experienced trial and appellate lawyer who has represented a wide range of clients in major product liability and other complex litigation, criminal investigations, actions by State Attorneys General, regulatory matters and litigation avoidance counseling. William has tried a number of cases to verdict in both state and federal court, has argued numerous appeals and conducted evidentiary hearings. He is a member of the DC Circuit’s Appointed Counsel Panel.
Samuel Lonergan (05/21/13)
Sam Lonergan concentrates his practice on complex commercial disputes with a particular focus on fraud and Deceptive Trade Practices Act (DTPA) matters and civil and criminal internal corporate investigations. He has litigated on behalf of clients in a wide range of industries, including pharmaceuticals, finance, telecommunications, aircraft and retail, always with a focus on providing practical advice that balances the client’s business needs with legal considerations.
Bert L. Slonim (05/13/13)
Bert Slonim concentrates on complex commercial litigation, particularly multi-district pharmaceutical product liability cases. He has represented manufacturers of prescription drugs (including hormone replacement therapy, erectile dysfunction, diabetes, antibiotic, and anti-psychotic medications), implanted medical devices, agricultural chemicals, electrical equipment, aerospace products, asbestos and other products. Much of his practice focuses on developing and rebutting expert medical and scientific evidence, and litigating the admissibility of expert opinion testimony.
Aton Arbisser (05/08/13)
Aton Arbisser is the Co-Chair of the Litigation Department of Kaye Scholer’s Los Angeles office and part of the firm’s Antitrust and Product Liability groups.
Arthur E. Brown (05/03/13)
Arthur E. Brown is Co-Chair of Kaye Scholer’s Product Liability Group, and a member of the firm’s Complex Commercial Litigation Group. His practice focuses on representing and advising clients on mass tort and product liability issues, investigations by federal and state authorities, inquiries from Congress, and commercial litigation disputes. As part of his practice, Arthur frequently serves as national counsel representing pharmaceutical companies in mass tort product liability actions, advises clients on strategic litigation and settlement decisions in the areas of commercial litigation and white collar investigations, and counsels clients on litigation avoidance.
Nicholas C. Friedman (04/30/13)
Nicholas Friedman is an Associate in Kaye Scholer’s Complex Commercial Litigation Department and a member of the Firm’s Life Sciences group. He represents clients in commercial, product liability and intellectual property litigation, with a particular focus on consolidated mass tort actions. Mr. Friedman has represented clients in all phases of litigation both in state and federal courts.
Sheila S. Boston (03/19/13)
Sheila S. Boston has a complex commercial litigation practice and is a member of Kaye Scholer’s Product Liability Group, which has been ranked in the top tier for Product Liability Litigation by Chambers USA in 2007-2011, was named Product Liability Firm of the Year at the 2008 Chambers and Partners “USA Awards for Excellence” ceremony, and was chosen by The American Lawyer as the 2006 Product Liability Department of the Year. Sheila has received individual recognition as she was listed in International Who’s Who of Product Liability Defense Lawyers in 2012.
Michel Antony Pignatiello (03/14/13)
Michel Pignatiello is an Associate in the Complex Commercial Litigation Department of Kaye Scholer’s New York office. Michel’s practice focuses primarily on pharmaceutical and medical device product liability and compliance. His experience includes representation of pharmaceutical and medical device companies in multidistrict litigation involving failure to warn and manufacturing defect allegations. He has also assisted in reviewing pharmaceutical compliance programs and counseling clients on applicable state and federal regulations.